Apolipoprotein C-III isoforms: Kinetics and relative implication in lipid metabolism

Journal of Lipid Research

Volumn 47, Issue 6, 2006, Pages 1212-1218

  Mauger, Jean François ^a   Couture, Patrick ^b   Bergeron, Nathalie ^c   Lamarche, Benoît ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

LDL particle size; Metabolic syndrome; Sialylation; Triglycerides; VLDL metabolism

Indexed keywords

APOLIPOPROTEIN C3; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOPROTEIN; LEUCINE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIALOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; HYPERTRIGLYCERIDEMIA; KINETICS; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN VARIANT; SIALYLATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; CHOLESTEROL; HUMANS; KINETICS; LIPID METABOLISM; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; PROTEIN ISOFORMS; STATISTICS;

EID: 33744809278     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M500455-JLR200     Document Type: Article

References (38)

1. Ruotolo, G., and B. V. Howard. 2002. Dyslipidemia of the metabolic syndrome. Curr. Cardiol. Rep. 4: 494-500.
2. Chan, D. C., H. P. Barrett, and G. F. Watts. 2004. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy. Am. J. Cardiovasc. Drugs. 4: 227-246.
3. van Dijk, K. W., P. C. Rensen, P. J. Voshol, and L. M. Havekes. 2004. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Curr. Opin. Lipidol. 15: 239-246.
4. Katzel, L. I., P. J. Coon, E. Rogus, R. M. Krauss, and A. P. Goldberg. 1995. Persistence of low HDL-C levels after weight reduction in older men with small LDL particles. Arterioscler. Thromb. Vasc. Biol. 15: 299-305.
5. McNamara, J., J. Jenner, Z. Li, P. Wilson, and E. Schaefer. 1992. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler. Thromb. 12: 1284-1290.
6. Jong, M. C., M. H. Hofker, and L. M. Havekes. 1999. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler. Thromb. Vasc. Biol. 19: 472-484.
7. Ito, Y., J. L. Breslow, and B. T. Chait. 1989. Apolipoprotein C-III0 lacks carbohydrate residues: use of mass spectrometry to study apolipoprotein structure. J. Lipid Res. 30: 1781-1787.
8. Juntti-Berggren, L., E. Refai, I. Appelskog, M. Andersson, G. Imreh, N. Dekki, S. Uhles, L. Yu, W. J. Griffiths, S. Zaitsev, et al. 2004. Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes. Proc. Natl. Acad. Sci. USA. 101: 10090-10094.
9. Gerritsen, G., P. C. Rensen, K. E, Kypreos, V. I. Zannis, L. M. Havekes, and v. D. Willems. 2005. ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression. J. Lipid Res. 46: 1466-1473.
10. Aalto-Setala, K., E. A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H. N. Ginsberg, and J. L. Breslow. 1992. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 90: 1889-1900.
11. Ebara, T., R. Ramakrishnan, G. Steiner, and N. S. Shachter. 1997. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J. Clin. Invest. 99: 2672-2681.
12. Shachter, N. S. 2001. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr. Opin. Lipidol. 12: 297-304.
13. Cohn, J. S., M. Tremblay, R. Batal, H. Jacques, C. Rodriguez, G. Steiner, O. Mamer, and J. Davignon. 2004. Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis. 177: 137-145.
14. Cohn, J. S., B. W. Patterson, K. D. Uffelman, J. Davignon, and G. Steiner. 2004. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J. Clin. Endocrinol. Metab. 89: 3949-3955.
15. Archer, W. R., B. Lamarche, O. Deriaz, N. Landry, L. Corneau, J. P. Despres, J. Bergeron, P. Couture, and N. Bergeron. 2003. Variations in body composition and plasma lipids in response to a high-carbohydrate diet. Obes. Res. 11: 978-986.
16. An, P., T. Rice, J. Gagnon, I. B. Borecki, J. Bergeron, J. P. Despres, A. S. Leon, J. S. Skinner, J. H. Wilmore, C. Bouchard, et al. 2000. Segregation analysis of apolipoproteins A-1 and B-100 measured before and after an exercise training program: the HERITAGE Family Study. Arterioscler. Thromb. Vasc. Biol. 20: 807-814.
17. Desroches, S., M. E. Paradis, M. Perusse, W. R. Archer, J. Bergeron, P. Couture, N. Bergeron, and B. Lamarche. 2004. Apolipoprotein A-I, A-II, and VLDL-B-100 metabolism in men: comparison of a lowfat diet and a high-monounsaturated fatty acid diet. J. Lipid Res. 45: 2331-2338.
18. Mauger, J. F., P. Couture, M. E. Paradis, and B. Lamarche. 2005. Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men. Atherosclerosis. 178: 157-163.
19. Bugugnani, M. J., M. Koffigan, I. Kora, D. Ouvry, V. Clavey, and J. C. Fruchart. 1984. Rapid assessment of the distribution of apolipoproteins C-II and C-III subspecies in triglyceride-rich lipoproteins by isoelectric focusing. Clin. Chem. 30: 349-351.
20. Dwyer, K. P., P. H. Barrett, D. Chan, J. I. Foo, G. F. Watts, and K. D. Croft. 2002. Oxazolinone derivative of leucine for GC-MS: a sensitive and robust method for stable isotope kinetic studies of lipoproteins. J. Lipid Res. 43: 344-349.
21. Cobelli, C., G. Toffolo, and D. M. Foster. 1992. Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am. J. Physiol. 262: 968-975.
22. Mauger, J. F., A. H. Lichtenstein, L. M. Ausman, S. M. Jalbert, M. Jauhiainen, C. Ehnholm, and B. Lamarche. 2003. Effect of different forms of dietary hydrogenated fats on LDL particle size. Am. J. Clin. Nutr. 78: 370-375.
23. Archer, W. R., B. Lamarche, O. Deriaz, N. Landry, L. Corneau, J. P. Despres, J. Bergeron, P. Couture, and N. Bergeron. 2003. Variations in body composition and plasma lipids in response to a high-carbohydrate diet. Obes. Res. 11: 978-986.
24. Huff, M. W., N. H. Fidge, P. J. Nestel, T. Billington, and B. Watson. 1981. Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects. J. Lipid Res. 22: 1235-1246.
25. Nestel, P. J., M. W. Huff, T. Billington, and N. H. Fidge. 1982. Changes in the plasma lipoprotein distribution of apolipoproteins C-II, C-III1, C-III2 and apolipoprotein B after heparin-induced lipolysis. Biochim. Biophys. Acta. 712: 94-102.
26. Huff, M. W., and P. J. Nestel. 1982. Metabolism of apolipoproteins CII, CIII1, CIII2 and VLDL-B in human subjects consuming high carbohydrate diets. Metabolism. 31: 493-498.
27. Kashyap, M. L., L. S. Srivastava, B. A. Hynd, P. S. Gartside, and G. Perisutti. 1981. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia. J. Lipid Res. 22: 800-810.
28. Harduin-Lepers, A., V. Vallejo-Ruiz, M. A. Krzewinski-Recchi, B. Samyn-Petit, S. Julien, and P. Delannoy. 2001. The human sialyl-transferase family. Biochimie. 83: 727-737.
29. Paulson, J. C. 1989. Glycoproteins: what are the sugar chains for? Trends Biochem. Sci. 14: 272-276.
30. Millar, J. S. 2001. The sialylation of plasma lipoproteins. Atherosclerosis. 154: 1-13.
31. Cohn, J. S., B. W. Patterson, K. D. Uffelman, J. Davignon, and G. Steiner. 2004. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J. Clin. Endocrinol. Metab. 89: 3949-3955.
32. Cohn, J. S., R. Batal, M. Tremblay, H. Jacques, L. Veilleux, C. Rodriguez, O. Mamer, and J. Davignon. 2003. Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism. J. Lipid Res. 44: 1976-1983.
33. Mann, C. J., A. A. Troussard, F. T. Yen, N. Hannouche, J. Najib, J. C. Fruchart, V. Lotteau, P. Andre, and B. E. Bihain. 1997. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor. J. Biol. Chem. 272: 31348-31354.
34. Holdsworth, G., J. Stocks, P. Dodson, and D. J. Galton. 1982. An abnormal triglyceride-rich lipoprotein containing excess sialylated apolipoprotein C-III. J. Clin. Invest. 69: 932-939.
35. Catapano, A. L. 1987. Activation of lipoprotein lipase by apolipoprotein C-II is modulated by the COOH terminal region of apolipoprotein C-III. Chem. Phys. Lipids. 45: 39-47.
36. Tornoci, L., C. A. Scheraldi, X. Li, H. Ide, I. J. Goldberg, and N. A. Le. 1993. Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins. J. Lipid Res. 34: 1793-1803.
37. Bukberg, P. R., N. A. Le, H. N. Ginsberg, J. C. Gibson, A. Rubinstein, and W. V. Brown. 1985. Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins. J. Lipid Res. 26: 1047-1057.
38. Batal, R., M. Tremblay, P. H. Barrett, H. Jacques, A. Fredenrich, O. Mamer, J. Davignon, and J. S. Cohn. 2000. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J. Lipid Res. 41: 706-718.